In order to have a better understanding of the clinical significance of Pseudomonas aeruginosa, circulating and secretory antibodies were measured. Of 100 patients diagnosed as having cystic fibrosis (CF) and an atypical mucoid P. aeruginosa cultured from their sputum, each possessed serum precipitins. These immunoprecipitates, however, were not detected in the sera of 40 CF patients, some of whom were chronically ill with pulmonary colonization by typically rough-smooth strains of P. aeruginosa. The sera of 46 CF patients and 27 CF patient parents not colonized by P. aeruginosa were negative for the precipitins. The sera from 15 of 45 chronically ill patients not having CF, however, but harboring P. aeruginosa, also possessed serum precipitins. The sera from 85 subjects not having CF and not clinically infected with P. aeruginosa were negative for precipitins. Serum hemagglutination titers as high as 1:4096 were measured in older CF patients having advanced pulmonary disease and who were infected with mucoid P. aeruginosa. Salivary titers ranged from 1:8 to 1:64. Increased levels of both circulating and secretory antibodies of the immunoglobulin A and G classes were demonstrated in patients with CF. Once a patient with CF becomes colonized with P. aeruginosa a process of conversion from the rough and smooth forms to the mucoid form is almost inevitable. Although the mucoid form predominates in the sputum, intermediates of the various colony types are often present. Serum precipitins were demonstrable only after the appearance of mucoid strains in the sputum of patients with CF. Although antibiotics tend to reduce the number of mucoid microorganisms, they are rarely, if ever, eradicated from these patients' lungs. Recurrent episodes of servere pulmonary infection and the evidence of increasing antibody formation to mucoid strains indicates the invasiveness of these particular strains.
Recurrent pulmonary infections are recognized as the major threat-to-life complications in most patients with cystic fibrosis (CF). Anderson (1), in 1938, described the morbid pathology seen in the lungs in patients with CF and stated that, in each of the 44 cases studied, there was evidence of respiratory infection. Blackfan and May (2) that same year described 35 cases of CF of the pancreas in which all patients died at an average age of 8 months and with widespread pulmonary infection. Staphylococcus aureus was the major pathogen responsible for these early infections. Longevity has increased with earlier detection and better pulmonary cleansing therapy; however, the major contribution to the prolongation of life has been the advent of antibiotics. Although morbidity has improved over the past decades, the general course is still one of steady deterioration. This is due, primarily, to pulmonary infections resulting from a combination of both antibiotic-resistant microorganisms and an apparent intrinsic defect in bacterial-clearance mechanisms.
Although respiratory infections are paramount in CF, evidence of septicemia is uncommon. Positive blood cultures are seldom obtained prior to death, even in the presence of superinfection resulting in massive pulmonary damage. The ability of these patients to provide adequate systemic protection, while their respiratory tract is highly vulnerable to infection, poses a situation which questions certain aspects of their respiratory defense mechanisms, namely, the secretory immune system. An investigation was conducted to determine specific circulatory and secretory antibodies and to compare the relative concentrations of such antibodies in the following major immunoglobulin (Ig) classes: IgG, IgM, and IgA.
Pseudomonas aeruginosa, particularly atypical mucoid strains, is now emerging as the predomi-nant pathogen associated with the terminal pulmonary manifestations in patients with CF. (8) . Antigens prepared from different strains were used to detect specific circulating and secretory antibodies and to measure certain parameters of the immune response in the presence of progressive lung disease.
MATERIALS AND METHODS
Serum samples from 186 patients, from 1 to 30 years of age and with a confirmed diagnosis of CF, and 27 heterozygous parents of CF patients were obtained and tested. Control subjects used were patients hospitalized at the Texas Institute for Rehabilitation and Research, Houston, Texas, and patients treated at the Pediatric Chest Clinic, Texas Children's Hospital, Houston, Texas. These control subjects were being treated for various chronic illnesses, such as other respiratory infections, and some of the subjects were postsurgery patients and urology patients. Whole saliva was collected and maintained at 4 C. The saliva was concentrated from 100 ml down to 5 ml by ultrafiltration, and molecules larger than 50,000 molecular weight were retained with Diaflo membranes (Amicon Corp., Lexington, Mass.). The saliva concentrate was kept at -20 C until tested.
Strains of P. aeruginosa were cultured and identified as previously described (13) . Strains A sample of fresh serum from individuals used in this study was first tested for immunoprecipitating antibodies by using the Ouchterlony double-diffusion technique. Sera exhibiting one or more reactive bands were also tested by using immunoelectrophoresis. An agar buffer, pH 8.2, with an ionicity of 0.075, was prepared by using 47.4 g of sodium barbitol, 690 ml of 0.1 N HCl, and 0.2 g of sodium azide. This was brought to a final volume of 4 liters with distilled water. The electrolyte buffer, pH 7.5, ionicity 0.150, was prepared with 34.4 g of sodium acetate, 34.4 g of sodium barbitol, and 3.88 ml of 12 N HCl. This buffer was brought to a final volume of 4 liters with distilled water. These buffers were prepared and refrigerated for at least 24 hr prior to use. The antigen preparations containing a dry weight of 50 mg of saline per ml were run at 40 ma and 100 v for 1 hr.
Hemagglutination test. Human type-0 erythrocytes (RBC) were used for this study because sheep RBC appeared to hemolyze more readily when sensitized with the P. aeruginiosa antigens. Purified P. aeruginiosa capsular polysaccharide (11) was dissolved in hemagglutination buffer (Difco) until saturated. This was used to prepare a 50N (v/v) working solution in the buffer. A 2%'' suspension of type-0 human RBC in the capsular-polysaccharide working solution was incubated for a period of 2 hr at 25 C and was gently mixed several times during this process. The solution was refrigerated overnight. The sensitized RBC were washed three times in hemagglutination buffer and resuspended, thus making a 2%r, RBC working solution in the buffer. The autoclaved serotype pool antigen preparation was used to sensitize RBC in a similar manner.
Indirect fluorescent-antibody test (IFA). The IFA procedure was essentially the same as that used by Tourville (22) 6, 1972 were shown to contain numerous antibodies when subjected to immunoelectrophoresis (Fig. 1) . The sera of 86 patients with CF, together with those of 27 heterozygous parents of CF patients not harboring a mucoid strain of P. aeruginosa, were negative for precipitins (Table 1) . Among these control subjects, five had mucoid strains and serum precipitins, and 45 had nonmucoid strains only, with 10 having serum precipitins. Figure 1 shows that autoclaving the antigen preparation destroyed a number of the antigens. These heat-labile antigens make up the bulk of the extracellular products; however, it is not known which of these substances are toxic and which are nontoxic at present. By substituting the antigen in the well with whole sera, one can observe that the major serum immunoglobulin classes, G, M, and A, contain antibodies.
Hemagglutination. The hemagglutination test using the serotype pool antigen demonstrated that serum titers of patients with CF ranged from 1:8 to 1:4096, whereas whole saliva never exceeded a titer of 1:16. The sonicated or crushed antigen preparations could not be used for they hemolyzed the RBC. Whether the capsular polysaccharide or the autoclaved serotype pool was used to sensitize the RBC, the titers of the individuals were essentially the same.
Quantitative immunoglobulins. There were no significant differences detected among the CF patients, heterozygous parents, or serum antibodies to Pseudomonas antigens are more common in those CF patients infected by mucoid strains of P. aeruginosa. The report of Burns and May (3) suggests that CF patients with mucoid strains of P. aeruginosa in their sputum possess Pseudomonas-specific precipitins and that the detection of such serum precipitins can be used as evidence of pathogenicity in such patients. This supports our earlier contention (8, 12) that atypical mucoid forms of P. aeruginosa were significant in the maintenance ofthe patients' pulmonary disease. These present findings have shown that patients with CF, without serum precipitins or mucoid Pseudomonas in the sputum, generally reflected a better clinical condition than did those having CF and possessing serum precipitins and mucoid Pseudomonas. The patients with CF who had high hemagglutination titers both to serotype pool and capsular polysaccharide antigens had clinical evidence of severe pulmonary disease. It has also been noted in this investigation that an increasing serum titer to Pseudomonas reflects a poor prognosis. Eleven of the patients with the higher titer have since expired due to respiratory insufficiency, with mucoid Pseudomonas being the final pathogen cultured not only from their sputum but also throughout their lungs shortly after death. Necropsy revealed that the lungs were filled with tenacious mucus and that many airways were plugged. Necrotic abscesses filled with purulent material were numerous throughout the lungs. Pure cultures of mucoid P. aeruginosa were cultured from these sites. Clinical and laboratory findings on these subjects prior to death failed to show evidence of sepsis in spite of the massive pulmonary infection. It is not presently known whether chemotherapeutic antibotics are responsible for this or if antibodies to Pseudomonas provide systemic protection. Apparently, little defense to the pulmonary tree against mucoid Pseudomonas is provided by either.
Hypergammaglobulinemia has been well documented in patients with CF and has been demonstrated by Schwartz (20) to be due to the elevation of the IgG and IgA serum immunoglobulins. South et al. (21) reported that the mean serum IgA levels were elevated in children with CF in contrast to normal controls. MartinezTello et al. (17) described a significant increase in the number of bronchial mucosa cells containing IgA and IgG in patients with CF and attributed this to severe bronchial inflammation.
The present findings suggest that the immunoglobulins present contain antibodies to P. aeruginosa. By using immunoelectrophoresis and fluorescent-antibody techniques, the serum immunoglobulins, IgG, IgM, and IgA, were found to contain specific antibodies. Although the relative concentrations of anti-Pseudomonas antibodies were greater in the serum IgG and IgM classes, secretory IgA was prominent in saliva.
Because it was determined that the immunoglobulin concentration is considerably affected by the rate of salivary flow and inflammation increases the transfer of most serum proteins into saliva, the results of the quantitation of the salivary immunoglobulins at this time appeared meaningless.
Of particular interest was the finding that Pseudomonas-specific precipitins could not be demonstrated in the sera of 40 patients with CF who harbored rough nonmucoid strains of P. aeruginosa in their sputum. This finding has several important implications concerning the role of P. aeruginosa in contributing to pathogenesis in this disease. It is generally recognized that microbial immunogens have to pass through the mucous epithelium into the lamina propria in order to evoke a considerable immune response. Accordingly, it appears that rough strains of P. aeruginosa represent surface or lumen colonization in this disease, whereas mucoid strains possess properties enabling these microorganisms to invade the respiratory lamina propria, thereby reaching the subject's immune system. Rough strains, no doubt, enter the lamina propria after tissue damage has occurred but are readily phagocytized by macrophages. One could speculate that the mucoid microorganisms are protected during phagocytosis by a thick coat of alginic acid (4, 16; Fig. 2, 3, and 4) degradation, because human tissue is not known to possess alginase. Additionally, it has been shown that the capsular polysaccharide of these mucoid strains is toxic to mouse (8) and chicken embryos (5) and that this toxic property is lost when the polysaccharide is degraded by alginase (5 whereby the viscid slime produced by these microorganisms obstructs airways in the lungs leading to respiratory insufficiency.
We have noted that some strains appear more virulent than others and that a suitable typing system is needed to determine when these virulent strains emerge so that increased chemotherapy can be initiated. We are now in the process of developing such a system.
